Acute myeloid leukemia (AML) based on progressed survival vs fashionable therapy in the past 2 decades, the healing landscape is currently poised to extend, with numerous new agents predicted to be authorised by means of the US Food and Drug Administration (FDA) in 2017 [1]. Midostaurin, a multitargeted fms-like tyrosine kinase 3 inhibitor, turned into authorized through the FDA in April 2017 [2]. Enasidenib, an isocitrate dehydrogenase 2–focused inhibitor; CPX-351, a liposomal daunorubicin/cytarabine combination; and gemtuzumab ozogamicin, a CD33-directed antibody-drug conjugate, had been FDA approved in August and September 2017 [[3], [4], [5]]. Additional centered treatment plans are being examined in phase three trials. Careful interpretation of endpoints utilized in past due-phase AML medical trials is critical to expertise and evaluating the efficacy of latest pills. Time-to-event (TTE) endpoints and scientific response rates are mainstays of AML clinical studies, but the endpoints exchange as trials circulate from early to past due segment. Even common endpoints are not usually pronounced in the equal manner across different trials, notwithstanding expert tips [6]. Moreover, some statistical results can be extra informative than others, depending at the observe kind, patient population, and duration of follow-up. This evaluate will talk a number of the nuances of commonplace AML trial endpoints and the way clinical trial records are presented to higher inform evaluation and information of the information as new treatment plans for AML emerge